Evidence map›Paper›PMID 38273048›Full record

ArticleOphthalmology and therapy2024

Comparison of Widefield OCT Angiography Features Between Severe Non-Proliferative and Proliferative Diabetic Retinopathy.

Ines Drira, Maha Noor, Amy Stone, Yvonne D'Souza, Binu John, Orlaith McGrath, Praveen J Patel, Tariq Aslam

Abstract read
In one paragraph

Article in Ophthalmology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Widefield optical coherence tomography angiography of fellow eyes in patients with Coats Disease.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ines DriraManchester University, Manchester Royal Eye Hospital, Oxford Rd, Manchester, M13 9WL, UK.ORCID http://orcid.org/0000-0001-5858-326X
Maha NoorManchester University, Manchester Royal Eye Hospital, Oxford Rd, Manchester, M13 9WL, UK.ORCID http://orcid.org/0000-0002-1486-469X
Amy StoneManchester University, Manchester Royal Eye Hospital, Oxford Rd, Manchester, M13 9WL, UK.
Yvonne D'SouzaManchester University, Manchester Royal Eye Hospital, Oxford Rd, Manchester, M13 9WL, UK.
Binu JohnManchester University, Manchester Royal Eye Hospital, Oxford Rd, Manchester, M13 9WL, UK.
Orlaith McGrathManchester University, Manchester Royal Eye Hospital, Oxford Rd, Manchester, M13 9WL, UK.ORCID http://orcid.org/0000-0002-4302-7081
Praveen J PatelNational Institute for Health and Care Research Biomedical Research Centre, Moorfields Eye Hospital National Health Service Foundation Trust and University College London Institute of Ophthalmology, London, UK.ORCID http://orcid.org/0000-0001-8682-4067
Tariq AslamManchester University, Manchester Royal Eye Hospital, Oxford Rd, Manchester, M13 9WL, UK. tariq.aslam@mft.nhs.uk.ORCID http://orcid.org/0000-0002-9739-7280

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere is a high and ever-increasing global prevalence of diabetic retinopathy (DR) and invasive imaging techniques are often required to confirm the presence of proliferative disease. The aim of this study was to explore the images of a rapid and non-invasive technique, widefield optical coherence tomography angiography (OCT-A), to study differences between patients with severe non-proliferative and proliferative DR (PDR).

methodsWe conducted an observational longitudinal study from November 2022 to March 2023. We recruited 75 patients who were classified into a proliferative group (28 patients) and severe non-proliferative group (47 patients). Classification was done by specialist clinicians who had full access to any multimodal imaging they required to be confident of their diagnosis, including fluorescein angiography. For all patients, we performed single-shot 4 × 4 and 10 × 10 mm (widefield) OCT-A imaging and when possible, the multiple images required for mosaic 17.5 × 17.5 mm (ultra widefield) OCT-A imaging. We assessed the frequency with which proliferative disease was identifiable solely from these OCT-A images and used custom-built MATLAB software to analyze the images and determine computerized metrics such as density and intensity of vessels, foveal avascular zone, and ischemic areas.

resultsOn clinically assessing the OCT-A 10 × 10 fields, we were only able to detect new vessels in 25% of known proliferative images. Using ultra-widefield mosaic images, however, we were able to detect new vessels in 100% of PDR patients. The image analysis metrics of 4 × 4 and 10 × 10 mm images did not show any significant differences between the two clinical groups. For mosaics, however, there were significant differences in the capillary density in patients with PDR compared to severe non-PDR (9.1% ± 1.9 in the PDR group versus 11.0% ± 1.9 for severe group). We also found with mosaics a significant difference in the metrics of ischemic areas; average area of ischemic zones (253,930.1 ± 108,636 for the proliferative group versus 149,104.2 ± 55,101.8 for the severe group.

conclusionsOur study showed a high sensitivity for detecting PDR using only ultra-widefield mosaic OCT-A imaging, compared to multimodal including fluorescein angiography imaging. It also suggests that image analysis of aspects such as ischemia levels may be useful in identifying higher risk groups as a warning sign for future conversion to neovascularization.

Indexed as

Fluorescein angiographyImage analysisNew vesselsOCT-AOCT-A metricsProliferative diabetic retinopathyRetinal ischemiaSevere diabetic retinopathy

Identifiers

PMID38273048
PMCPMC10853160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.